A Multicenter, Phase 1b, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Si 544 (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Adverse reactions
- Sponsors selectION
Most Recent Events
- 08 Apr 2025 Planned End Date changed from 31 May 2025 to 31 Jul 2025.
- 08 Apr 2025 Planned primary completion date changed from 31 May 2025 to 31 Jul 2025.
- 23 Jan 2025 Planned End Date changed from 31 Mar 2025 to 31 May 2025.